Search
for

    Did you mean Transient Receptor Potential Vanilloid 1?
    Glossary Transient Receptor Potential Vanilloid 1

    protein channel that detects heat, acidity, and capsaicin

    Transient Receptor Potential Vanilloid 1 (TRPV1), also known as the Capsaicin Receptor, is a protein found on the surface of certain cells, including sensory neurons. It acts as an ion channel that opens in response to heat, acidic conditions, and capsaicin (the compound that makes chili peppers hot), playing a crucial role in the sensation of pain and temperature.

    Related Terms

    Research

    5 / 1000+ results

    Community Join

    5 / 1000+ results

      community Dutasteride absolutely nukes hair DHT

      in Finasteride/Dutasteride  486 upvotes 1 year ago
      Dutasteride significantly reduces DHT levels, potentially more effectively than finasteride, and is used to treat hair loss. Some users report side effects like reduced libido and mood changes, while others experience hair regrowth and increased testosterone.

      community Amplifica: Hope or Cope? A Review of Their Pipeline

       9 upvotes 4 weeks ago
      Amplifica's AMP-303 showed a modest increase in hair growth, but results were inconsistent and potentially misleading. Hyaluronic acid and osteopontin are being explored for hair growth, with varying effects on different hair types and conditions.

      community It all feels like a pointless cope

      in Chat  17 upvotes 5 months ago
      The user is frustrated with hair loss despite using finasteride and is considering a hairpiece as a solution. Suggestions include trying a buzz cut, considering dutasteride or oral minoxidil, and addressing potential dietary issues.

      community GT20029 China Phase II Trial For AGA Reached Primary Endpoint

       133 upvotes 2 years ago
      The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.